# Aflibercept 2mg Treat-and-Extend Protocol
# Based on meta-analysis of pivotal and real-world studies June 2025
# Extraction date: 2025-06-08
# Sources: VIEW 1/2, ALTAIR, FRB! registry, HAGA, Maruko, Aslanis

# Required metadata
name: "Aflibercept 2mg Treat-and-Extend"
version: "1.0.0"
created_date: "2025-06-08"
author: "Clinical Economics Integration Team"
description: "Aflibercept 2mg treat-and-extend protocol synthesizing RCT and real-world evidence"

# Core protocol parameters
protocol_type: "treat_and_extend"
min_interval_days: 56        # 8 weeks (ALTAIR minimum)
max_interval_days: 112       # 16 weeks (ALTAIR maximum)
extension_days: 14           # 2 weeks (ALTAIR protocol)
shortening_days: 14          # 2 weeks (symmetric with extension)

# Required disease transitions - Meta-analysis of ALTAIR T&E and VIEW fixed dosing
# Note: Combining ALTAIR treat-and-extend transitions with VIEW outcomes
disease_transitions:
  NAIVE:
    NAIVE: 0.00
    STABLE: 0.59      # ALTAIR: 55-60% achieve extension after loading
    ACTIVE: 0.33      # ALTAIR: 30-35% maintain 8-week interval
    HIGHLY_ACTIVE: 0.08
    
  STABLE:
    NAIVE: 0.00
    STABLE: 0.83      # ALTAIR: 80-85% maintain extended intervals
    ACTIVE: 0.12      # ALTAIR: 10-15% revert to shorter intervals
    HIGHLY_ACTIVE: 0.05
    
  ACTIVE:
    NAIVE: 0.00
    STABLE: 0.33      # ALTAIR: 30-35% achieve extension
    ACTIVE: 0.57      # ALTAIR: 55-60% maintain current interval
    HIGHLY_ACTIVE: 0.10
    
  HIGHLY_ACTIVE:
    NAIVE: 0.00
    STABLE: 0.08      # ALTAIR: 5-10% direct improvement (rare)
    ACTIVE: 0.35      # ALTAIR: 30-40% stabilize to active
    HIGHLY_ACTIVE: 0.57  # ALTAIR: 50-65% remain highly active

# Required vision change model - Based on VIEW 1/2 trials and project parameters
# Note: Using actual aflibercept 2mg data from VIEW studies
vision_change_model:
  naive_treated:
    mean: 8.4          # From VIEW 1/2 combined (52 weeks)
    std: 14.7          # From VIEW 1/2 combined
    
  naive_untreated:
    mean: -2.5         # From project data (natural history)
    std: 2.0
    
  stable_treated:
    mean: 1.0          # From project data (0.1-1.5 range)
    std: 1.5
    
  stable_untreated:
    mean: -0.75        # From project data
    std: 1.0
    
  active_treated:
    mean: 0.3          # From project data (-0.2 to +0.8 range)
    std: 2.0
    
  active_untreated:
    mean: -2.0         # From project data
    std: 2.5
    
  highly_active_treated:
    mean: -0.3         # From project data (-0.8 to +0.3 range)
    std: 3.0
    
  highly_active_untreated:
    mean: -4.0         # From project data
    std: 3.5

# Vision loss during unplanned gaps (Evidence-based from COVID-era analysis)
# Applied when treatment gaps exceed normal protocol intervals
gap_vision_loss_model:
  short_gap_90_180_days:
    monthly_rate: -0.47      # letters/month
    total_impact: -5.9       # net impact including partial recovery
    recovery_probability: 0.505
    
  long_gap_180_365_days:
    monthly_rate: -0.81      # letters/month  
    total_impact: -8.1       # net impact including partial recovery
    recovery_probability: 0.554
    
  discontinuation_365_plus_days:
    monthly_rate: -0.51      # letters/month (plateaus)
    total_impact: -11.8      # limited recovery
    recovery_probability: 0.20

# Treatment effect on transitions - Based on project standards
treatment_effect_on_transitions:
  NAIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.5        # Treatment promotes stability
      ACTIVE: 0.7        # Reduces progression to active
      HIGHLY_ACTIVE: 0.5 # Significantly reduces progression to highly active
      
  STABLE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.2        # Helps maintain stability
      ACTIVE: 0.75       # Reduces deterioration
      HIGHLY_ACTIVE: 0.6
      
  ACTIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.4        # Promotes return to stable
      ACTIVE: 0.9
      HIGHLY_ACTIVE: 0.7
      
  HIGHLY_ACTIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.5        # Strong treatment effect for severe disease
      ACTIVE: 1.2
      HIGHLY_ACTIVE: 0.8

# Baseline vision parameters
baseline_vision:
  mean: 55             # Typical trial entry criteria
  std: 15
  min: 25              # Minimum for treatment (guidance threshold)
  max: 85

# Discontinuation rules - Based on current best practice
# Note: This standard protocol does NOT include inappropriate clinical discontinuations
# For real-world modeling with clinical errors, use aflibercept_2mg_treat_and_extend_sash.yaml
discontinuation_rules:
  # Stable disease at extended interval
  stable_extended_interval:
    criteria:
      consecutive_stable_visits: 3
      minimum_interval_weeks: 7     # Cannot extend beyond this
    probability: 0.10
    reason: "stable_disease"
    
  # Poor response - primary criterion
  poor_response_25_letters:
    criteria:
      va_less_than: 25              # < 25 letters absolute
      consecutive_visits: 2         # On 2 consecutive visits
      attributable_to_amd: true
    probability: 0.95
    reason: "poor_response"
    
  # Critical vision loss
  critical_vision_15_letters:
    criteria:
      va_less_than: 15              # < 15 letters absolute
      consecutive_visits: 2
    probability: 0.99
    reason: "severe_vision_loss"
    
  # Unable to extend intervals
  frequent_injections:
    criteria:
      max_achieved_interval_weeks: 7  # Cannot extend beyond 7 weeks
      attempts: 2                     # After 2 failed extension attempts
      months_on_treatment: 12
    probability: 0.50                # May switch or stop
    reason: "treatment_burden"
    
  # Non-compliance
  non_compliance:
    criteria:
      missed_consecutive_visits: 2
      months_since_last_visit: 4
    probability: 0.95
    reason: "lost_to_follow_up"
    
  # Adverse events
  adverse_event:
    criteria:
      severe_adverse_event: true
    probability: 0.90
    reason: "adverse_event"

# Protocol-specific parameters
treat_and_extend_parameters:
  # Loading phase - Based on standard practice
  loading_phase:
    number_of_doses: 3
    interval_days: 28               # Monthly
    
  # Extension/reduction rules
  extension_rules:
    stable_criteria:
      no_disease_activity: true     # OCT dry
      va_stable_or_improved: true
    extend_by_days: 14              # 2 weeks
    max_extension_days: 28          # Up to 4 weeks per guidance
    
  reduction_rules:
    active_criteria:
      disease_activity: true        # OCT shows fluid
      va_deterioration: true        # Loss of letters
    reduce_by_days: 14              # 2 weeks
    min_interval_days: 28           # Not less than monthly
    
  # Treatment switching criteria
  switch_criteria:
    suboptimal_after_loading: true
    frequent_injections_threshold_weeks: 8
    failed_extension_attempts: 2
    
  # Maximum lines of therapy
  max_lines_of_therapy: 3

# Unplanned gap scenarios (External disruptions like COVID)
# Based on real-world evidence but excluding clinical decision errors
unplanned_gap_scenarios:
  external_short_gap:
    duration_days: [90, 180]
    probability: 0.094              # 9.4% in COVID era
    va_impact: -5.9                 # letters net
    recovery_potential: 0.505
    
  external_long_gap:
    duration_days: [180, 365]
    probability: 0.025              # 2.5% in COVID era
    va_impact: -8.1                 # letters net
    recovery_potential: 0.554

# Clinical evidence basis
clinical_evidence:
  source: "Meta-analysis of RCT and real-world studies (n>5,000 eyes)"
  key_data:
    - "VIEW 1/2: Mean +8.4 letters at 52 weeks (SD 14.7) - RCT"
    - "ALTAIR: 41-46% maintain 16-week intervals at 96 weeks - RCT"
    - "FRB! registry: +4.2 letters at 24 months - Real-world"
    - "Aslanis: 52.9% recurrence at 12 months post-discontinuation"
  injection_burden:
    - "ALTAIR RCT: 10.4 injections over 2 years"
    - "FRB! real-world: 14.9 injections over 2 years"
    - "Maruko: 13.0 injections over 2 years (max 12-week intervals)"
    - "HAGA: 7.5 injections year 1 (76% optimal responders)"
  extension_patterns:
    - "ALTAIR: 59% achieve extension after loading, max 16 weeks"
    - "Maruko: 60.8% at 12-week intervals by 2 years (conservative protocol)"
    - "FRB!: Maximum ~10 weeks achieved in real-world practice"
    - "HAGA: 76% achieve 7 injections/year with 12-week maximum"
  population_insights:
    - "Japanese studies (ALTAIR, HAGA, Maruko): Higher PCV prevalence (36-76%)"
    - "FRB! international: Real-world discontinuation 28-33% at 2 years"
    - "Visual gains vary: +4.2 (real-world) to +13-16 (HAGA small study)"
  key_principles:
    - "First choice: Aflibercept 2mg (switch to biosimilar when available)"
    - "Maximum 3 lines of therapy per eye"
    - "Switch if unable to extend beyond 8 weeks after 2 attempts"
    - "Real-world outcomes typically lower than RCT results"
  gap_consequence_evidence:
    - "COVID-era analysis: 11.9% experienced treatment gaps"
    - "Mean VA loss during gaps: 0.47-0.81 letters/month"
    - "Recovery rates: 50-55% show partial recovery"
    - "Net impact: -5.9 to -8.1 letters depending on gap duration"
  data_synthesis:
    - "Transitions from ALTAIR T&E study (n=247)"
    - "Vision outcomes from VIEW 1/2 (n=1,217)"
    - "Real-world patterns from FRB! registry (n=3,313)"
    - "Conservative protocols from Japanese studies (n=185)"
    - "Recurrence model from Aslanis (n=102)"
    - "Gap consequences from COVID-era analysis (n=21,727 intervals)"